Health

Health

Public health, medicine, mental health, outbreaks, and healthcare systems.

health

FDA Approves Lembaz for Infantile-Onset Niemann-Pick Type C, First Treatment Shown to Extend Survival

FDA approves Lembaz (adrabetadex) for infantile-onset Niemann-Pick type C — the first therapy shown to extend survival in this ultra-rare childhood disorder.

#fda, #rare-disease, #npc, #drug-approval

health

U.S. Loses Measles Elimination Status After 26 Years, PAHO Says

PAHO says the U.S. has lost measles elimination status after sustained 2025 transmission. CDC reports 5,412 confirmed cases and falling MMR coverage.

#measles, #vaccination, #cdc, #publichealth

health

FDA Approves Sunharbo, First Factor XIa Inhibitor, to Reduce Recurrent Ischemic Stroke in High‑Risk Adults

FDA approved Sunharbo (asundexian), the first U.S. factor XIa inhibitor, to prevent recurrent ischemic stroke in certain high‑risk adults alongside antiplatelet therapy.

#stroke, #asundexian, #fda, #bayer, #fxia

health

FDA Grants Accelerated Approval to Rybrevant Faspro for Recurrent, Metastatic Head and Neck Cancer

FDA grants accelerated approval to Janssen's Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma after chemo and immunotherapy.

#oncology, #fda, #drugapproval, #headandneck, #janssen

health

Registry Analysis Finds No Statistically Detectable Mortality Difference Between PCI and CABG for Left Main Coronary Disease

An IRIS‑MAIN registry analysis found no statistically detectable long‑term mortality difference between PCI with drug‑eluting stents and CABG for left‑main disease; results are observational.

#leftmain, #pci, #cabg, #cardiology, #clinicaltrials

health

Bias-Adjusted Study Finds About 75% of Deceased Former NFL Players Had CTE

Bias-adjusted analysis of 2,362 deceased former NFL players estimates 74.5% had CTE at death, underscoring a large neurological burden.

#cte, #nfl, #concussion, #brainhealth, #research

health

UK regulator extends Casgevy gene‑editing therapy to children aged 5 and over

MHRA has extended Casgevy (exa‑cel) approval to children aged 5+, widening access to CRISPR stem‑cell therapy for severe sickle‑cell disease and β‑thalassemia.

$VRTX, #health, #geneediting, #sicklecell, #vertex

health

CMS flagged multiple contractors for early problems in Medicare WISeR prior-authorization pilot

Newly released records show CMS cited delayed decisions, disputed denials and portal failures at multiple contractors during early months of the WISeR Medicare pilot.

#medicare, #cms, #priorauthorization, #healthcare

health

Pfizer says ELREXFIO improved progression-free survival in Phase 3 trial; results are interim

Pfizer reports interim Phase 3 results showing ELREXFIO improved progression-free survival in earlier-line multiple myeloma; safety and overall survival under review.

$PFE, #pfizer, #elrexfio, #elranatamab, #multiplemyeloma, #clinicaltrials

health

FDA Expands Approval of Talzenna Plus Xtandi for HRR‑Mutated Metastatic Castration‑Sensitive Prostate Cancer

FDA on Oct. 26 approved Talzenna plus Xtandi for HRR‑mutated metastatic castration‑sensitive prostate cancer; genetic testing required.

$PFE, #fda, #prostatecancer, #oncology, #pfizer

health

Pfizer’s 25‑valent infant pneumococcal vaccine showed immune responses to all 25 serotypes in Phase 2, company reports

Pfizer's 25‑valent infant pneumococcal vaccine elicited immune responses to all 25 serotypes in Phase 2, with safety similar to Prevnar 20 and stronger serotype 3 responses.

$PFE, #vaccine, #pneumococcal, #pfizer, #pediatrics

health

NICHE‑2 phase 2 follow‑up: short‑course neoadjuvant immunotherapy linked to 100% 3‑year disease‑free survival in dMMR colon cancer

NICHE‑2 reports 100% 3‑year disease‑free survival after brief neoadjuvant ipilimumab+nivolumab for dMMR colon cancer; single‑arm results need confirmation.

#immunotherapy, #colon-cancer, #clinical-trial, #dmmr

health

FDA Approves Hibsago, First Antisense Therapy for Chronic Hepatitis B, for Select Adults

FDA approves Hibsago (bepirovirsen), the first antisense drug for chronic hepatitis B, offering some adults a monitored path off long-term antivirals.

$GSK, #hepatitis_b, #fda, #gsk, #bepirovirsen

health

FDA Grants Accelerated Approval for GSK’s Jemperli in Biomarker-Defined Locally Advanced Rectal Cancer

FDA grants accelerated approval to GSK’s Jemperli for adults with stage II–III dMMR/MSI‑H locally advanced rectal cancer, potentially avoiding surgery.

$GSK, #health, #cancer, #fda, #immunotherapy

health

UK medicines regulator opens consultation on schools keeping adrenaline nasal sprays

MHRA opens eight-week UK consultation on allowing schools to stock spare adrenaline nasal sprays as an alternative to auto-injectors for treating anaphylaxis.

#health, #allergies, #schools, #mhra